Drug Development in Case of Glaucoma

Kunal Joon*

Noida International Institute of Medical Sciences, Haryana, India

***Corresponding Author:** Kunal Joon, Noida International Institute of Medical Sciences, Haryana, India.*

Abstract

Glaucoma is characterised by a progressive degeneration of optic nerve with Corresponding visual loss and ultimately blindness if left untreated.

Keywords: Glaucoma; Degeneration; Neuro Ophthalmology; Blindness; Visual Loss; Drug Statistics

Drug development

Figure 1

Patient trials were carried out and following observation were observed as shown in the figure [1]. These compounds shown in the compounds are the compounds included in the trials [2]. Each compounds is categorized according to IOP lowering, vascular and neuro protective [3].


Figure 2

Figure 2 shows compounds on ongoing trials, trials completed foe 2 years and [4] compounds approved for treatment of glaucoma these are linked to the right target site. The colour indicates whether a compound is neuroprotective (dark green), [5] vascular (orange) and IOP lowering (light green) [6].

Treatment

IOSP laser surgery [7], fluorescence surgery [8] and laser light surgery stem cell therapy [8]. Amniocentesis [9].

Discussion

- Drug development in case of glaucoma [10]
- Drug trials

Conclusion

Drug development trials in the glaucoma.

Bibliography

1. https://pubmed.ncbi.nlm.nih.gov/26182236
2. https://pubmed.ncbi.nlm.nih.gov/26111782
3. https://pubmed.ncbi.nlm.nih.gov/19574692/
4. https://pubmed.ncbi.nlm.nih.gov/18170651/
5. https://pubmed.ncbi.nlm.nih.gov/22346129/
6. https://pubmed.ncbi.nlm.nih.gov/23556149/
7. https://pubmed.ncbi.nlm.nih.gov/27014388
8. https://pubmed.ncbi.nlm.nih.gov/575877/
9. https://pubmed.ncbi.nlm.nih.gov/33519186
10. https://pubmed.ncbi.nlm.nih.gov/30089089/